Europe — EMA
Nephromag (Mertiatide)
GNH USA supplies Nephromag (Mertiatide), a therapeutic agent for investigational renal and transplant applications. Request a quote for global supply.
Request sourcing
What is Mertiatide?
Mertiatide, the active ingredient in Nephromag, is an investigational compound presented as an intravenous formulation for parenteral use. It is being evaluated for potential therapeutic applications in renal and transplant medicine. Current data are limited and it is not yet approved for specific indications.
GNH USA supplies Nephromag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.
What is Mertiatide used for?
Nephromag (Mertiatide) is an investigational agent studied in renal and transplant‑related pathways.
- No approved indication: currently under clinical investigation for renal transplantation. - No approved indication: currently under clinical investigation for acute kidney injury. - No approved indication: currently under clinical investigation for chronic kidney disease.
What are the side effects of Mertiatide?
Adverse reactions have not been comprehensively documented for Mertiatide.
Common Side Effects: - None reported: no data available. - None reported: no data available.
Serious or Rare Side Effects: - None reported: no data available. - None reported: no data available.
What precautions apply to Mertiatide?
Given the limited safety information, careful clinical monitoring is advised.
- Clinical monitoring: observe patients closely for any unexpected reactions. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Renal function: assess baseline function before administration. - Allergy: discontinue if hypersensitivity signs appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.
What does Mertiatide interact with?
Potential drug interactions have not been fully characterized.
Major Interactions (Avoid): - None reported: no known major drug interactions.
Moderate Interactions (Monitor Closely): - Potential interaction with nephrotoxic agents: monitor renal function. - Concurrent use with immunosuppressants: observe for additive immunosuppression. - Co‑administration with anticoagulants: watch for altered bleeding risk. - Interaction with contrast media: assess renal impact.
